Scleroderma Market Report 2026

The scleroderma market size has grown strongly in recent years. It will grow from $2.48 billion in 2025 to $2.65 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to rising prevalence of systemic sclerosis, use of immunosuppressive therapies, availability of antifibrotic agents, growth of specialty rheumatology clinics, increasing awareness of connective tissue disorders.

The scleroderma market size is expected to see strong growth in the next few years. It will grow to $3.48 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to pipeline of novel disease-modifying drugs, adoption of telehealth for chronic disease management, growth in multidisciplinary care models, increased government funding for rare disease research, expansion of patient education and support programs. Major trends in the forecast period include development and approval of novel disease-modifying therapies, increased use of immunosuppressive and antifibrotic agents, growth of patient support and early intervention programs, expansion of systemic scleroderma clinical trials, adoption of multidisciplinary care approaches for chronic management.

Exposure to toxins is driving growth in the scleroderma market. Toxin exposure refers to contact with or ingestion of harmful substances that can negatively impact biological systems. The scleroderma market addresses this challenge by advancing research, developing targeted therapies, and improving patient care for individuals affected by scleroderma, a disease influenced by both environmental and genetic factors. For example, data published by the UK Department for Environment, Food, and Rural Affairs in April 2024 indicated that urban background concentrations increased by 3 percent from 2022, reaching 66.8 µg/m³ in 2023, the highest value recorded in the time series. This rise in toxin exposure is a key factor driving the scleroderma market.

Major companies in the scleroderma market are focusing on product launches, such as clinical trial platforms, to advance treatments and identify therapies suitable for progression from Phase IIb to Phase III trials. A clinical trial platform provides a standardized infrastructure and framework to evaluate multiple therapies simultaneously across different trials. For instance, in August 2023, the US-based Scleroderma Research Foundation (SRF) launched CONQUEST, a global clinical trial platform with enrollment across 130 centers in 22 countries. Using a master protocol to assess multiple therapies, this initiative is expected to accelerate the development and approval of effective scleroderma treatments through its collaborative and efficient approach.

In October 2023, Amgen Inc., a US biotechnology company, acquired Horizon Therapeutics plc for approximately $27.8 billion. This acquisition strengthens Amgen’s portfolio of first-in-class therapies for rare inflammatory diseases, aligns with its strategy of delivering innovative treatments, and leverages its biologics research and manufacturing capabilities to improve global patient outcomes. Horizon Therapeutics plc, based in Ireland, is involved in treating scleroderma through its therapy Fipaxalparant.

Major companies operating in the scleroderma market are Pfizer Inc., Johnson And Johnson Inc., F. Hoffmann-La Roche AG, Abbvie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., GSK plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Principia Biopharma Corp, aTyr Pharma Inc., Kadmon Holdings Inc., FibroGen Inc., Corbus Pharmaceuticals Holdings Inc., CSL Behring, UCB Pharma, Kyowa Kirin, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical Co. Ltd.

North America was the largest region in the scleroderma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleroderma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the scleroderma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the scleroderma market by raising costs for imported immunosuppressive drugs, antifibrotic therapies, and specialized medical devices used in systemic sclerosis management. Rheumatology clinics, hospitals, and specialty pharmacies in Asia-Pacific and Europe are most affected due to dependency on imported therapies. Despite increased costs and supply chain challenges, tariffs have promoted local manufacturing, regional sourcing, and development of cost-effective therapies, supporting long-term market stability and patient access.

The scleroderma market research report is one of a series of new reports that provides scleroderma market statistics, including scleroderma industry global market size, regional shares, competitors with a scleroderma market share, detailed scleroderma market segments, market trends and opportunities, and any further data you may need to thrive in the scleroderma industry. This scleroderma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Scleroderma is a rare, chronic autoimmune disorder marked by abnormal collagen growth, a protein that forms the structure of the skin and other tissues. Treatments aim to prevent or control excessive collagen production, manage symptoms effectively, and reduce the risk of complications associated with the disease.

The main treatments for scleroderma include medications, surgery, and other approaches. Medications are substances, typically in the form of drugs or pharmaceuticals, used to prevent, treat, or manage medical conditions, diseases, or symptoms. These treatments are indicated for both systemic and localized scleroderma and are provided through hospitals, pharmaceutical stores, and other channels.

The scleroderma market consists of revenues earned by entities by providing dilation of blood vessels, immunosuppressants, relieving pain, and reducing infection. The market value includes the value of related goods sold by the service provider or included within the service offering. The scleroderma market also includes the sales of methotrexate, anti-thymocyte globulin, mycophenolate mofetil, and cyclophosphamide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.